Perspective Therapeutics, Inc. (CATX)
1.155
-0.10
(-7.60%)
USD |
NYAM |
Oct 29, 16:00
1.155
0.00 (0.00%)
After-Hours: 20:00
Perspective Therapeutics Enterprise Value : -90.31M for Oct. 28, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 28, 2026 | -90.31M |
| October 27, 2026 | -97.15M |
| October 26, 2026 | -94.87M |
| October 23, 2026 | -49.23M |
| October 22, 2026 | 24.92M |
| October 21, 2026 | 29.48M |
| October 20, 2026 | 29.48M |
| October 19, 2026 | 16.94M |
| October 16, 2026 | 14.65M |
| October 15, 2026 | 34.05M |
| October 14, 2026 | 22.64M |
| October 13, 2026 | 26.06M |
| October 12, 2026 | 54.58M |
| October 09, 2026 | 70.56M |
| October 08, 2026 | 76.26M |
| October 07, 2026 | 47.74M |
| October 06, 2026 | 36.33M |
| October 05, 2026 | 60.29M |
| October 02, 2026 | 81.96M |
| October 01, 2026 | 77.40M |
| September 30, 2026 | 80.82M |
| September 29, 2026 | 65.99M |
| September 28, 2026 | 52.30M |
| September 25, 2026 | 54.58M |
| September 24, 2026 | 52.30M |
| Date | Value |
|---|---|
| September 23, 2026 | 65.99M |
| September 22, 2026 | 104.78M |
| September 21, 2026 | 105.92M |
| September 18, 2026 | 95.66M |
| September 17, 2026 | 95.66M |
| September 16, 2026 | 75.12M |
| September 15, 2026 | 78.54M |
| September 14, 2026 | 100.22M |
| September 11, 2026 | 87.67M |
| September 10, 2026 | 83.11M |
| September 09, 2026 | 108.20M |
| September 08, 2026 | 123.04M |
| September 04, 2026 | 124.18M |
| September 03, 2026 | 123.04M |
| September 02, 2026 | 120.75M |
| September 01, 2026 | 120.75M |
| August 31, 2026 | 127.60M |
| August 28, 2026 | 121.89M |
| August 27, 2026 | 129.88M |
| August 26, 2026 | 127.60M |
| August 25, 2026 | 142.43M |
| August 24, 2026 | 131.02M |
| August 21, 2026 | 143.57M |
| August 20, 2026 | 133.30M |
| August 19, 2026 | 164.11M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Anika Therapeutics, Inc. | 275.24M |
| MiMedx Group, Inc. | 456.98M |
| ABVC BioPharma, Inc. | 32.86M |
| Enovis Corp. | 2.622B |
| Edwards Lifesciences Corp. | 49.48B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -26.98M |
| Revenue (Quarterly) | 0.081M |
| Total Expenses (Quarterly) | 27.06M |
| EPS Diluted (Quarterly) | -0.222 |
| Gross Profit Margin (Quarterly) | -1.31K% |
| Profit Margin (Quarterly) | -33.31K% |
| Earnings Yield | -115.0% |
| Normalized Earnings Yield | -106.88 |